NeuroSense Therapeutics Ltd. NRSN
6.95
(0.45)
(6.08%)
as of 25 Sep
- Market cap
- $14.0M
- P/E
- 0.0×
Follow NRSN
Insider Buys
alert about insiders buying in the last 12 month
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 24.68 | 6.38 | 19.12 | 4.28 | 0.84 | 2.21 | 0.31 |
Net Debt/EBITDA |
— | 0.72 | 0.26 | 1.99 | 0.52 | 0.22 | 0.35 | 0.01 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 1.91% | 2.29% | 0.00% | 7.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.03 | (0.04) | 0.00 | (0.05) |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.48 | 0.25 | 0.38 | 0.61 | 0.83 | 0.99 | 0.69 |
Capex/Depreciation |
— | 0.00 | (3.00) | (5.67) | (0.79) | (1.38) | (0.14) | (0.50) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 0.00% | (358.66%) | (83.62%) | (168.75%) | (523.68%) | (2,478.16%) | (2,174.98%) | |
| — | (255.92%) | (326.18%) | (66.19%) | (128.94%) | (185.53%) | (263.14%) | (397.11%) | |
ROIC |
— | (3,355.98%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (138.39%) | (429.14%) | (37.30%) | (215.28%) | 2,206.77% | (412.36%) | 662.20% |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (2.54) | (2.55) | (4.98) | (13.31) | (12.29) | (10.90) | (6.03) |
Cash per Share |
— | 3.86 | 2.67 | 35.56 | 12.39 | 3.93 | 3.67 | 0.17 |
Shareholders Equity per Share |
— | 3.96 | 2.39 | 28.85 | 9.77 | (2.58) | 2.78 | (1.22) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 3.96 | 2.39 | 28.85 | 9.77 | (2.58) | 2.78 | (1.22) |
Free Cash Flow |
— | (0.59) | (0.70) | (1.56) | (7.66) | (8.38) | (10.14) | (7.68) |
Working Capital |
— | 0.88 | 0.65 | 10.82 | 5.66 | (0.54) | 2.41 | (1.74) |
Capital Expenditures |
— | (0.01) | (0.01) | (0.02) | (0.07) | (0.03) | 0.00 | (0.01) |
Net Current Asset Value |
— | 0.88 | 0.65 | 8.99 | 5.29 | (2.03) | 2.41 | (1.81) |
| Other line items | ||||||||
Quick Ratio |
— | 24.68 | 6.38 | 19.12 | 4.28 | 0.84 | 2.21 | 0.31 |
Depreciation/Fixed assets |
— | 0.00 | 0.23 | 0.16 | 1.16 | 0.25 | 0.33 | 0.28 |
Cash ROIC |
— | (32.49%) | (50.75%) | (7.75%) | (59.44%) | (848.99%) | (170.13%) | 606.20% |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (2.51) | (2.52) | (4.93) | (13.19) | (12.25) | (10.90) | (6.02) |
Capex per Share |
— | (0.03) | (0.03) | (0.05) | (0.12) | (0.04) | 0.00 | (0.01) |
Average Receivables |
— | — | 0.02 | 0.17 | 0.28 | 0.25 | 0.61 | 0.78 |
Average Payables |
— | — | 0.04 | 0.05 | 0.27 | 0.98 | 1.31 | 0.98 |
Average Assets |
— | 0.48 | 0.87 | 6.11 | 9.57 | 5.45 | 3.88 | 2.80 |
Average Common Equity |
— | — | 0.79 | 4.83 | 7.31 | 1.93 | 0.41 | 0.51 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates